Why Revance Therapeutics Stock Is Jumping 13.1% Today
After the company announced an exclusive U.S. licensing deal to market multiple fillers used in cosmetic procedures, Revance Therapeutics shares (NASDAQ: RVNC) were up 13.1% at 12:30 p.m. EST on Friday.
Investors were hoping Revance Therapeutics would make the leap from clinical-stage to commercial-stage biotech stock this year pending Food and Drug Administration approval of DAXI, a long-lasting formulation of a neurotoxin designed to compete against Allergan's (NYSE: AGN) Botox.
Image source: Getty Images.
Source Fool.com
